Open AccessNew Treatment Options in Advanced Stage Follicular Lymphoma
Author(s) -
Hübel Kai,
Salles Gilles,
Marcus Robert,
Zinzani Pier Luigi,
Dreyling Martin
Publication year - 2018
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/hs9.0000000000000156
Subject(s) - follicular lymphoma , medicine , lymphoma , oncology , clinical trial , follicular phase , stage (stratigraphy) , chemotherapy , biology , paleontology
Follicular lymphoma is one of the most common non‐Hodgkin's lymphomas with an expected survival of more than 20 years for the majority of patients. This impressive outcome has been achieved with the introduction of immunochemotherapy, as first line treatment with remissions lasting over 8 years, followed by other treatment options at first or subsequent relapse. However, certain groups of patients still have a poor prognosis. In recent years the efficacy of chemotherapy regimens has been augmented by new compounds selectively targeting the cell surface, intracellular pathways, and/or the microenvironment. Some of these are beginning to change the therapeutic landscape. This review summarizes prognostic factors in follicular lymphoma in order to identify patients with greatest medical need for these new treatment options and reviews recent data from prospective clinical studies testing new agents in first‐line and relapsed follicular lymphoma. Finally, we assess the current role of immunochemotherapy and discuss the requirements for future clinical trials.